Paul Bisaro
CIK 1237253 · Executive Chairman · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.39M
Companies
13
Total Filings
132
Lifetime Open-Market Net
-$38.45M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MYGN | Director | 157,142 | $4.33 | $680.4K | $27.6K | 6 | 2026-06-05 |
| ZTS | Director | 27,862 | $79.57 | $2.22M | $151.8K | 24 | 2026-05-13 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 71,131 | $0.34 | $24.2K | $42.3K | 5 | 2023-06-29 |
| TXMD | Director | 5,922 | $2.20 | $13.0K | $96.5K | 7 | 2022-10-03 |
| AMRX | Executive Chairman | 29,454 | $16.20 | $477.2K | $203.5K | 4 | 2019-05-09 |
| Allergan plc (AGN) Delisted | Director | 383,729 | — | — | $0 | 3 | 2018-05-04 |
| Allergan plc (AGNpA) Delisted | Director | 385,253 | — | — | -$16.97M | 10 | 2018-01-02 |
| ZIMMER BIOMET HOLDINGS, INC. (ZMHw) Delisted | Director | — | — | — | $0 | 15 | 2017-04-04 |
| Impax Laboratories, LLC (IPXL) Delisted | President and CEO | — | — | — | $0 | 1 | 2017-03-29 |
| Allergan plc (ACTpA) Delisted | Exec Chairman | 422,531 | — | — | $0 | 1 | 2015-03-09 |
| ACT | President & CEO | 0 | $42.41 | $0 | $0 | 1 | 2013-10-02 |
| Actavis, Inc. (WPI) Delisted | President & CEO | 307,339 | — | — | $0 | 12 | 2012-03-16 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | 133,078 | — | — | -$22.00M | 25 | 2007-10-24 |
Recent Filings · Page 2 of 14
132 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-06 | MYGN | Grant (A) | +49,796 | $0 | EDGAR |
| 2025-02-20 | ZTS | Grant (A) | — | $0 | EDGAR |
| 2025-02-11 | ZTS | Exer (M) | +1,225 | $0 | EDGAR |
| 2025-02-10 | ZTS | Exer (M) | +1,236 | $0 | EDGAR |
| 2025-01-02 | — | Mixed | +2,018 | $0 | |
| 2024-06-07 | MYGN | Grant (A) | +15,695 | $0 | EDGAR |
| 2024-02-20 | — | Grant (A) | — | $0 | |
| 2024-02-13 | ZTS | Exer (M) | +1,463 | $0 | EDGAR |
| 2024-02-12 | ZTS | Exer (M) | +1,493 | $0 | EDGAR |
| 2024-02-08 | ZTS | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.